BCG Vaccine Market Overview:
Global BCG Vaccine Market was valued at $20,366 thousands in 2016, and is estimated to reach $28,051 thousands by 2023, growing at a CAGR of 4.6% from 2017 to 2023. Bacillus Calmette-Gurin (BCG) vaccine is the only vaccine currently available for prevention of tuberculosis (TB). In countries with high prevalence of tuberculosis, one dose is recommended for healthy babies close to the time of birth. However, in areas where tuberculosis is uncommon, only children at high risk are typically immunized, while suspected cases of tuberculosis are individually tested and treated. Adults not infected with tuberculosis and who have not been previously immunized but are frequently exposed to drug-resistant tuberculosis may be immunized as well.
The factors that drive the global BCG vaccine market include increase in prevalence of tuberculosis, especially in developing and underdeveloped countries, and technological advancement in the field of vaccine research. Moreover, the increase in government initiatives and focus on immunization programs globally further boost the market growth. However, side effects of BCG vaccine and a global shortage of this vaccine restricts this growth. Untapped market opportunities in developing regions are expected to provide numerous prospects for market development.
BCG Vaccine Market Segmentation
The pediatrics segment held a major share of the BCG vaccine market in 2016, and is expected to maintain its dominance throughout the forecast period. BCG is generally administered to all the infants up to one year of age in countries where BCG vaccination is a part of the national childhood immunization program. In addition, this vaccine can also be given to older children (more than 1 year of age) who have increased risk of developing tuberculosis. It is rarely given above the age of 16, and never administered above the age of 35 as vaccinations are effective only when administered in early stages of life.
BCG Vaccine Market, by Demographics, 2016 (%)
Snapshot of Kenya BCG Vaccine Market
BCG vaccination is part of the immunization schedule of the Kenya Expanded Program on Immunization (KEPI). Therefore, the vaccine is administered to all the children born in Kenyan hospitals. The vaccine is administered as an injection (single dose) on the left forearm of infants immediately after birth. Moreover, in this region, BCG vaccine is generally given along with polio and Hepatitis B vaccines to infants after birth.
Kenya BCG Vaccine Market, 2016-2023 ($Thousand)
The list of key players profiled in this report include Merck & Co., Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group (a subsidiary of China National Pharmaceutical Group Corporation), Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited (GSBPL), and Statens Serum Institut.
Key Benefits :
- The study provides an in-depth analysis of the market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.
- Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
BCG Vaccine Market Key Segments:
- Pediatrics (0-18 years)
- Adults (19-35 years)
- South Africa
- Rest of the world